Article
A platinum-based hybrid drug design approach to circumvent acquired resistance to molecular targeted tyrosine kinase inhibitors.
Scientific reports - 6 May 2016
Wei Yuming, Poon Daniel C, Fei Rong, Lam Amy S M, Au-Yeung Steve C F, To Kenneth K W
Abstract excerpt
Three molecular targeted tyrosine kinase inhibitors (TKI) were conjugated to classical platinum-based drugs with an aim to circumvent TKI resistance, predominately mediated by the emergence of secondary mutations on oncogenic kinases. The hybrids were found to maintain specificity towards the same oncogenic kinases as the original TKI. Importantly, they are remarkably less affected by TKI resistance, presumably...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.